Investor Presentaiton
Hematology
Reblozyl BET Inhibitor Breyanzi golcadomide Abecma
alnuctamab
GPRC5D
iber/mezi
KarMMa-21: Strong data supports advancing Abecma into
Phase 3 KarMMa-9 study
Response, %
100%
80%
Overall Response Rate
ORR, 87.1%
ISCR
■CR
■ VGPR
PR
48.4%
60%
CR, 74.2%
40%
25.8%
20%
0%
9.7%
3.2%
n=31
PFS, %
100-
90-
80
70-
60-
50-
40-
30-
8 8 8 8 8 8 8 8
Progression-Free Survival
Safety
Grade ≥3
n=31
90.1% (SE: 5.43)
83.1% (SE: 6.89)
H
CRS
0
iiNT
3.2%
Infections
12.9%
20-
10-
All patients N=31
Number of events n=6
Median: 30.7 months
(95% CI; NE, NE)
0.
Manageable
tolerability profile
0
-2
T
T
T
T
T
T
T
T
4
6
8
10
12 14 16 18 20 22 24 26 28 30
8-
-
32
with low rates of Gr≥3
Time, months
NT and infections and
At risk 31
31 29 29 29 29
27 27 27 26 26 26 22 15
9
3
0
no Gr≥3 CRS
KarMMa-2 Cohort 2c studied Abecma in patients with clinical high-risk MM due to inadequate response (<VGPR) to frontline ASCT
ll Bristol Myers Squibb™ 1. Dhodapkar M, et al. ASH 2022 [Presentation #3314].
Not for Product Promotional Use
83View entire presentation